Rapid disappearance of influenza following the implementation of COVID-19 mitigation measures in Hamilton, Ontario

Kevin Zhang,1,* Avika Misra,2 Patrick J. Kim,3 Seyed M. Moghadas,4 Joanne M. Langley,5 Marek Smieja3,6

1Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, M5S 1A8
2Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada, K1H 8M5
3Department of Medicine, McMaster University, Hamilton, Ontario, Canada, L8S 4L8
4Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada, M3J 1P3
5Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada, B3K 6R8
6St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada, L8N 4A6

*Corresponding author: kevink.zhang@mail.utoronto.ca

Keywords: COVID-19, influenza, testing, public health interventions

Abstract

Background: Public health measures, such as social distancing and closure of schools and non-essential services were rapidly implemented in Canada to interrupt the spread of the novel coronavirus disease 2019 (COVID-19).

Objective: We sought to investigate the impact of mitigation measures during the spring wave of COVID-19 on the incidence of other laboratory-confirmed respiratory viruses in Hamilton, Ontario.

Methods: All nasopharyngeal swab specimens (n = 57,503) submitted for routine respiratory virus testing at a regional laboratory serving all acute-care hospitals in Hamilton, Ontario between January 2010 and June 2020 were reviewed. Testing for influenza A/B, respiratory syncytial virus, human metapneumovirus, parainfluenza I–III, adenovirus and rhinovirus/enterovirus was done routinely using a laboratory-developed polymerase chain reaction multiplex respiratory viral panel. A Bayesian linear regression model was used to determine the trend of positivity rates of all influenza samples for the first 26 weeks of each year from 2010 to 2019. The mean positivity rate of Bayesian inference was compared with the weekly reported positivity rate of influenza samples in 2020.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
**Results:** The positivity rate of influenza in 2020 diminished sharply following the population-wide implementation of COVID-19 interventions. Weeks 12-26 reported 0% positivity for influenza, with the exception of 0.1% reported in week 13.

**Conclusions:** Public health measures implemented during the COVID-19 pandemic have had a clear impact on suppressing the incidence of other respiratory viruses and should be considered to mitigate severe seasonal influenza and other respiratory virus pandemics.

**Introduction**

The novel coronavirus disease 2019 (COVID-19) has led to devastating global morbidity and mortality (1), even in the presence of public health measures including social distancing and unprecedented movement restrictions (2–5). These restrictive measures have helped to mitigate COVID-19 transmission (6,7), but have led to widespread disruptions to the economy (8,9), trade (10), and education (11). Following the declaration of COVID-19 as a pandemic on March 11 by the World Health Organization (3), the province of Ontario, Canada announced the closure of all schools and non-essential workplaces (2,4). Months later, public health measures, such as social distancing and mask-wearing continue to be in place to reduce the toll associated with the COVID-19 pandemic (5).

Public health measures have reduced the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Ontario (7). Similarly, previous studies evaluating the effect of mitigation measures during flu pandemics have demonstrated significant reductions in influenza transmission (12,13). Given that annual outbreaks of seasonal influenza in Ontario often lead to long term care outbreaks, crowded emergency rooms, and significant mortality despite vaccination, we evaluated the effect of COVID-19 interventions on the transmission of non-COVID-19 respiratory viruses, including seasonal influenza. We found that the positivity rate of influenza dropped to 0% shortly after the implementation of public health measures, deviating from the general trend inferred from a Bayesian linear regression for the preceding ten years. Our results may provide evidence for the use of mitigation strategies, such as social distancing and mask-wearing, to combat future seasonal influenza outbreaks and other respiratory viruses with pandemic potential.

**Methods**

**Sampling and testing**

We reviewed all nasopharyngeal swab specimens (n = 57,503) submitted for routine respiratory virus testing at a regional laboratory serving all acute-care hospitals in Hamilton, Ontario between January 2010 and June 2020.

Testing was done using a Taqman real-time reverse transcription polymerase chain reaction multiplex respiratory viral panel, developed by the Hamilton Regional Laboratory Medicine Program, for influenza A/B, respiratory syncytial virus, human metapneumovirus, parainfluenza
I–III, adenovirus, and rhinovirus/enterovirus. On March 16, 2020, parainfluenza II was replaced by the SARS-CoV-2 virus. Sample RNA extraction and amplification were primarily performed on the bioMérieux NucliSENS easyMag and QIAGEN Rotor-Gene Q, respectively, from 2010-2019 and primarily performed on the BD MAX System from July 2019-2020. Clinical results were validated by experienced staff and recorded into a laboratory information system, following standard operating procedures.

Data

A respiratory virus database with all test results and demographic information is updated weekly, and has been in place since 2010. A 10-years data cut with basic demographic information (age, sex, postal code, date, facility, accession number) and test results were exported from the laboratory database on June 29, 2020. Results were filtered by postal code to exclude samples from persons living outside of Hamilton, Ontario.

Ethics approval

The study was approved by the Hamilton Integrated Research Ethics Board (Project: 07-2923). The study was categorized as minimal risk, defined as no potential for negative impact on the health and safety of the participant, and waiver of individual consent for participation was obtained.

Statistical analysis

We used a Bayesian linear regression model with uninformative prior distributions to determine the trend of positivity rates of all influenza A/B samples for the first 26 weeks of each year from 2010-2019 (Appendix: Table A1). We then compared the mean positivity rate of Bayesian inference with the weekly reported positivity rate of influenza samples in 2020 (Appendix: Table A2).

The hierarchical regression model has the form

\[ y \sim \text{Normal}(\mu, \sigma) \]
\[ \mu = \beta^T x \]
\[ \beta = \text{Normal}(0, 100) \]
\[ \sigma^2 = \text{InverseGamma}(2.5, 25) \]

where \( y \) represents the positivity rate over the first 26 weeks (variable \( x \)) of each year from 2010-2019. All parameters were sampled using Markov Chain Monte Carlo (MCMC) simulations in three independent chains. Each chain consisted of 10,000 iterations, with a burn-in period of 1,000 iterations and a thinning factor of 5. To assess convergence, we inspected the trace plots and applied the Gelman-Rubin convergence test by computing the potential scale reduction factors (PSRF). All PSRF values were computed to be less than 1.1 (and remained close to 1), indicating the convergence of the model parameters to their posterior distributions. We used the posterior distributions of the parameters (\( \beta_1, \beta_2, \sigma \)) from our Bayesian analysis to derive mean estimates and credible intervals (Appendix: Table A3) by employing the method of Highest Posterior Density (14).
Results

A description of individuals’ attributes included in our study is provided in Table 1. A total of 57,503 patients were tested for respiratory viruses in Hamilton, Ontario in 2010-2020, of which 48.6% (n = 27,971) were male and 27.6% (n = 15,879) were children. The bimodal age distribution had a median age of adults of 68.9 years (IQR: 53.5 - 81.5) and 1.7 years among children (IQR: 0.5 - 4.7). A median of 4924 (IQR: 3440 - 6636) samples were tested each year, with a mean influenza positivity rate of 9.0% (SD: 3.3%). Mean percent positivity was also calculated for respiratory syncytial virus (4.7%, SD: 6.4%), metapneumovirus (2.4%, SD: 3.0%), parainfluenza (3.7%, SD: 4.0%), adenovirus (1.1%, SD: 1.4%), and rhinovirus/enterovirus (9.4%, SD: 10.5%).

Table 1. Demographics, sample size, and positivity rate of laboratory-confirmed respiratory viruses in Hamilton, Ontario in 2010-2020 (n = 57,503)

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years, adults</td>
<td>68.9 (53.5 - 81.5)</td>
</tr>
<tr>
<td>Age in years, children</td>
<td>1.7 (0.5 - 4.7)</td>
</tr>
<tr>
<td>Male</td>
<td>27,971 (48.6%)</td>
</tr>
<tr>
<td>Adults</td>
<td>41,618 (72.4%)</td>
</tr>
<tr>
<td>Children</td>
<td>15,879 (27.6%)</td>
</tr>
<tr>
<td>Respiratory virus samples</td>
<td></td>
</tr>
<tr>
<td>Samples per year</td>
<td>4924 (3440 - 6636)</td>
</tr>
<tr>
<td>Positivity rate</td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>9.0% (3.3%)</td>
</tr>
<tr>
<td>Respiratory syncytial virus</td>
<td>4.7% (6.4%)</td>
</tr>
<tr>
<td>Metapneumovirus</td>
<td>2.4% (3.0%)</td>
</tr>
<tr>
<td>Parainfluenza</td>
<td>3.7% (4.0%)</td>
</tr>
<tr>
<td>Adenovirus</td>
<td>1.1% (1.4%)</td>
</tr>
<tr>
<td>Rhinovirus/enterovirus</td>
<td>9.4% (10.5%)</td>
</tr>
</tbody>
</table>

Figure 1 illustrates the mean positivity rate derived from posterior distributions of parameters in the Bayesian linear regression model using positivity rates reported for 2010-2019 (black curve). The positivity rate of influenza in 2020 (red curve) was highest at 17.7% in week 1, and dropped below the 95% CrI for the preceding 10 years after the first week, with an ensuing declining
trend (Figure 1; Appendix: Table A2). Following the implementation of COVID-19 interventions during week 12 (from March 12, 2020; grey bar in Figure 1), the positivity rate of influenza diminished sharply and remained at 0% for weeks 12-26, with the exception of 0.1% reported in week 13.

**Figure 1.** Bayesian inference for the mean positivity rate (black curve) and its 95% CrI (blue shaded area) of influenza A and B for the first 26 weeks in 2010-2019. The red curve shows the positivity rate of influenza A and B for 2020, with the shaded grey bar indicating the start of COVID-19 lockdown.

**Discussion**

The impact of mitigation measures has been observed across other respiratory viruses transmitted in a similar manner to COVID-19. For example, school closures and social distancing in response to the 2009 H1N1 pandemic in Mexico resulted in a 27-29% reduction in influenza transmission during the spring wave (12). During the 1957-1958 influenza pandemic, school closures contributed to reducing the attack rate by over 90% (13). Similarly, following the implementation of COVID-19 mitigation measures, the influenza positivity rate was suppressed in the United States (15,16). Our results suggest that COVID-19 public health measures may have contributed to a substantial disruption of the spread of influenza in Hamilton, Ontario.

The 2020 influenza season was observed to be relatively mild in Hamilton, Ontario, as compared to previous seasons (Appendix: Table A1, A2). However, the lower positivity rate observed in our analysis (Figure 1), may be attributed to several factors including increased precautions taken as a result of initial news reporting of the spread of COVID-19 in China and global dissemination, normal seasonal variation, in addition to changes in sampling behaviour and increased testing. For the 2010-2019 seasons, the median influenza positivity rate reached
0% by week 23. In 2020, however, after the implementation of COVID-19 mitigation measures, percent positivity for influenza dropped precipitously to 0% in week 12. The Centers for Disease Control and Prevention reported similar findings through their weekly influenza surveillance system, in which the percent positivity for influenza decreased from 7.5% in week 12 to 1.0% in week 14, suggesting that COVID-19 mitigation measures may be slowing progression in laboratory-confirmed influenza cases in the United States (15,16). Moreover, the positivity rates for respiratory syncytial virus, metapneumovirus, parainfluenza, adenovirus, and rhinovirus/enterovirus were reported to be 0% by week 14 of 2020 (Appendix: Table A2), indicating the impact of lockdown measures on suppressing the transmission of other respiratory viruses.

The findings of our study should be interpreted in the context of study limitations. First, respiratory samples were not collected systematically, but rather they were obtained as part of routine clinical care. As such, the samples may not fully represent the prevalence of respiratory viruses in the region. It is also possible that clinicians may not have strictly followed hospital infection control policy and failed to sample patients who otherwise would have been eligible. Furthermore, sampling behaviour may have changed during the early stage of COVID-19 spread in Canada. However, these factors are unlikely to change our conclusions due to the near-elimination of the absolute number of laboratory-confirmed respiratory virus cases, despite the large increase in testing which accompanied concern for COVID-19 in the community.

Our findings suggest that efforts to control the COVID-19 pandemic may have had additional benefits in suppressing the transmission of other respiratory viruses in Hamilton, Ontario. Mitigation strategies, such as social distancing, mask-wearing, and school closures could play an important role in combating future seasonal respiratory viruses and emerging infectious diseases with pandemic potential.

Authors’ statement

KZ, AM, PJK, SMM, and MS contributed to the conception and design of the work. KZ, SMM, JML, and MS contributed to the acquisition of data, analysis, and interpretation of results. All authors drafted, read, and approved the final manuscript.

Competing interests

Joanne Langley reports that Dalhousie University has received payment for the conduct of vaccine studies from Sanofi, Glaxo-SmithKline, Merck, Janssen, VBI and Pfizer. Dr. Langley holds the Canadian Institutes of Health Research-GlaxoSmithKline Chair in Pediatric Vaccinology. No other competing interests were declared.

Funding

References


16. Blum K. Was Social Distancing a Help in Slowing the Flu Season? [Internet]. [cited 2020